title: Lenalidomide and chronic lymphocytic leukemia.
abstract: Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance. This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies.
authors.affiliation: Department of Hematology, Hospital Universitario Central de Asturias, C/Celestino Villamil s/n, 33006 Oviedo, Spain.
authors.forename: Ana Pilar
authors.initials: AP
authors.lastname: González-Rodríguez
authors.forename: Angel R
authors.initials: AR
authors.lastname: Payer
authors.forename: Andrea
authors.initials: A
authors.lastname: Acebes-Huerta
authors.forename: Leticia
authors.initials: L
authors.lastname: Huergo-Zapico
authors.forename: Monica
authors.initials: M
authors.lastname: Villa-Alvarez
authors.forename: Esther
authors.initials: E
authors.lastname: Gonzalez-García
authors.forename: Segundo
authors.initials: S
authors.lastname: Gonzalez
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D056747:Immunomodulation; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D000069283:Rituximab; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D013792:Thalidomide; D000077269:Lenalidomide